Pfizer Inc. (NYSE:PFE) Shares Purchased by Tectonic Advisors LLC

Tectonic Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 244,619 shares of the biopharmaceutical company’s stock after buying an additional 20,933 shares during the period. Tectonic Advisors LLC’s holdings in Pfizer were worth $6,199,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the period. Geode Capital Management LLC raised its stake in shares of Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer during the 4th quarter worth about $2,328,986,000. Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. Finally, Northern Trust Corp increased its position in Pfizer by 7.7% in the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 1.2%

PFE stock opened at $25.36 on Tuesday. The stock has a market capitalization of $144.15 billion, a P/E ratio of 18.37, a P/E/G ratio of 0.93 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business has a fifty day moving average price of $23.92 and a 200-day moving average price of $24.77.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.78%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s payout ratio is 124.64%.

Wall Street Analyst Weigh In

Several research firms have weighed in on PFE. TD Cowen lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research report on Tuesday, April 22nd. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.